BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 5, 2025
See today's BioWorld
Home
» GTx Nixes Toremifene After Ipsen Terminates Partnership
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
GTx Nixes Toremifene After Ipsen Terminates Partnership
March 3, 2011
By
Marie Powers
No Comments
GTx Inc. plans to walk away from toremifene after the company "mutually agreed to terminate" its collaboration with Ipsen Group SA to develop and commercialize the drug, GTx CEO Mitchell Steiner told BioWorld Today.
BioWorld
